Senores Pharmaceuticals - Public Comps and Valuation Multiples

Senores Pharmaceuticals Overview

About Senores Pharmaceuticals

Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.

Founded

2017

HQ

Employees

194

Website

senorespharma.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $57.7M

LTM EBITDA $14.7M

EV

$352M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Senores Pharmaceuticals Financials

As of August 2025, Senores Pharmaceuticals reported last 12-month revenue of $57.7M and EBITDA of $14.7M.

In the same period, Senores Pharmaceuticals generated $29.0M in LTM gross profit and $8.9M in net income.

See Senores Pharmaceuticals valuation multiples based on analyst estimates

Senores Pharmaceuticals P&L

In the most recent fiscal year, Senores Pharmaceuticals reported revenue of $43.4M and EBITDA of $12.2M.

Senores Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Senores Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$57.7M	XXX	$43.4M	XXX	XXX	XXX
Gross Profit	$29.0M	XXX	$21.9M	XXX	XXX	XXX
Gross Margin	50%	XXX	50%	XXX	XXX	XXX
EBITDA	$14.7M	XXX	$12.2M	XXX	XXX	XXX
EBITDA Margin	26%	XXX	28%	XXX	XXX	XXX
EBIT	$12.4M	XXX	$8.3M	XXX	XXX	XXX
EBIT Margin	21%	XXX	19%	XXX	XXX	XXX
Net Profit	$8.9M	XXX	$6.6M	XXX	XXX	XXX
Net Margin	15%	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	XXX	$22.6M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Senores Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $57.7M. EBITDA for the last twelve months was $14.7M. In the most recent fiscal year, Senores Pharmaceuticals achieved $43.4M in revenue and $12.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$57.7M	Analyst estimates available to subscribers	$43.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$29.0M	Analyst estimates available to subscribers	$21.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	50.2% gross margin	Analyst estimates available to subscribers	50.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$14.7M	Analyst estimates available to subscribers	$12.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	25.5% EBITDA margin	Analyst estimates available to subscribers	28.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$12.4M	Analyst estimates available to subscribers	$8.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	21.4% EBIT margin	Analyst estimates available to subscribers	19.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$8.9M	Analyst estimates available to subscribers	$6.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	15.4% net profit margin	Analyst estimates available to subscribers	15.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$22.6M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Senores Pharmaceuticals

This financial data table provides comprehensive performance metrics for Senores Pharmaceuticals, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Senores Pharmaceuticals generated $57.7M in revenue over the last twelve months.
The company achieved $14.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $29.0M.
Net income over the last twelve months reached $8.9M.

Fiscal Year Performance

In the most recent fiscal year, Senores Pharmaceuticals reported $43.4M in total revenue.
Fiscal year EBITDA was $12.2M.
The company maintained a gross profit margin of 50.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 28.2%.
Net profit margin reached 15.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Senores Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Senores Pharmaceuticals Stock Performance

Senores Pharmaceuticals has current market cap of INR 31.8B (or $360M), and EV of INR 31.1B (or $352M).

Market Cap Evolution

Senores Pharmaceuticals Stock Data

As of September 12, 2025, Senores Pharmaceuticals's stock price is INR 690 (or $8).

See Senores Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$352M	$360M	XXX	XXX	XXX	XXX	$0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Senores Pharmaceuticals Valuation Multiples

Senores Pharmaceuticals's trades at 9.1x EV/Revenue multiple, and 33.9x EV/EBITDA.

See valuation multiples for Senores Pharmaceuticals and 15K+ public comps

Senores Pharmaceuticals Financial Valuation Multiples

As of September 12, 2025, Senores Pharmaceuticals has market cap of $360M and EV of $352M.

Equity research analysts estimate Senores Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Senores Pharmaceuticals has a P/E ratio of 40.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$360M	XXX	$360M	XXX	XXX	XXX
EV (current)	$352M	XXX	$352M	XXX	XXX	XXX
EV/Revenue	6.1x	XXX	9.1x	XXX	XXX	XXX
EV/EBITDA	23.9x	XXX	33.9x	XXX	XXX	XXX
EV/EBIT	28.5x	XXX	49.7x	XXX	XXX	XXX
EV/Gross Profit	12.2x	XXX	n/a	XXX	XXX	XXX
P/E	40.4x	XXX	61.4x	XXX	XXX	XXX
EV/FCF	-86.3x	XXX	-18.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Senores Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Senores Pharmaceuticals Margins & Growth Rates

Senores Pharmaceuticals's last 12 month revenue growth is 40%

Senores Pharmaceuticals's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Senores Pharmaceuticals's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Senores Pharmaceuticals's rule of X is 126% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Senores Pharmaceuticals and other 15K+ public comps

Senores Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	40%	XXX	50%	XXX	XXX	XXX
EBITDA Margin	26%	XXX	27%	XXX	XXX	XXX
EBITDA Growth	52%	XXX	53%	XXX	XXX	XXX
Rule of 40	67%	XXX	67%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	126%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	31%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial